The combination of Bristol Myers Squibb cancer drugs Opdivo and Yervoy landed FDA approvals for the first-line treatment of colorectal cancer and hepatocellular carcinoma. Several other products also expanded their approved uses in our recap of recent regulatory news.
Kyoto University's Tasuku Honjo and MD Anderson's James Allison will share the prize for work that led to immunotherapy drugs like Keytruda and Yervoy.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
The company, with ARIAD and Intellia veterans at the helm, aims to develop CTLA4-targeting monoclonal antibody that mitigates the immune toxicity of Bristol's Yervoy.